ResMed - RMD Stock Forecast, Price & News

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last twelve months. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RMD shares.
View RMD analyst ratings or view top-rated stocks.

9 brokerages have issued twelve-month price targets for ResMed's shares. Their RMD share price forecasts range from $250.00 to $280.00. On average, they expect the company's stock price to reach $266.40 in the next year. This suggests a possible upside of 14.9% from the stock's current price.
View analysts price targets for RMD or view top-rated stocks among Wall Street analysts.

ResMed's stock was trading at $260.48 on January 1st, 2022. Since then, RMD shares have decreased by 11.0% and is now trading at $231.76.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 27th 2022.
View our RMD earnings forecast.

ResMed Inc. (NYSE:RMD) posted its quarterly earnings results on Thursday, August, 11th. The medical equipment provider reported $1.49 EPS for the quarter, beating analysts' consensus estimates of $1.48 by $0.01. The medical equipment provider had revenue of $914.74 million for the quarter, compared to analysts' expectations of $912.53 million. ResMed had a net margin of 21.78% and a trailing twelve-month return on equity of 26.56%. The firm's revenue was up 4.4% compared to the same quarter last year. During the same period last year, the business earned $1.35 EPS.
Read the conference call transcript.

ResMed declared a quarterly dividend on Friday, August 12th. Investors of record on Thursday, August 18th will be paid a dividend of $0.44 per share on Thursday, September 22nd. This represents a $1.76 annualized dividend and a dividend yield of 0.76%. The ex-dividend date of this dividend is Wednesday, August 17th. This is an increase from the stock's previous quarterly dividend of $0.42.
Read our dividend analysis for RMD.

ResMed (NYSE:RMD) pays an annual dividend of $1.76 per share and currently has a dividend yield of 0.77%. The company has been increasing its dividend for 2 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 33.15%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, RMD will have a dividend payout ratio of 23.47% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for RMD.

284 employees have rated ResMed Chief Executive Officer Mick Farrell on Glassdoor.com. Mick Farrell has an approval rating of 92% among the company's employees. This puts Mick Farrell in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other ResMed investors own include NVIDIA (NVDA), Walt Disney (DIS), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Adobe (ADBE), Visa (V), Alibaba Group (BABA), PayPal (PYPL) and QUALCOMM (QCOM).

ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD."

ResMed's stock is owned by a variety of retail and institutional investors. Top institutional investors include Capital Investment Services of America Inc. (0.09%), First Hawaiian Bank (0.01%), Wedmont Private Capital (0.00%) and Park National Corp OH (0.00%). Insiders that own company stock include Brett Sandercock, Carol Burt, Dave Michaud, David Pendarvis, James Hollingshead, Justin Leong, Michael J Farrell, Michael J Farrell, Rajwant Sodhi, Richard Mchale, Robert Andrew Douglas and Ronald R Taylor.
View institutional ownership trends.

Shares of RMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RMD stock can currently be purchased for approximately $231.76.

ResMed (NYSE:RMD) has a market capitalization of $33.94 billion and generates $3.58 billion in revenue each year. The medical equipment provider earns $779.44 million in net income (profit) each year or $5.31 on an earnings per share basis.

The company employs 8,160 workers across the globe.

ResMed's mailing address is 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123. The official website for the company is www.resmed.com. The medical equipment provider can be reached via phone at (858) 836-5000, via email at investorrelations@resmed.com, or via fax at 858-836-5501.